12 results on '"Takayanagi, T."'
Search Results
2. g Theorem from Strong Subadditivity.
- Author
-
Harper J, Kanda H, Takayanagi T, and Tasuki K
- Abstract
We show that strong subadditivity provides a simple derivation of the g theorem for the boundary renormalization group flow in two-dimensional conformal field theories. We work out its holographic interpretation and also give a derivation of the g theorem for the case of an interface in two-dimensional conformal field theories. We also geometrically confirm strong subadditivity for holographic duals of conformal field theories on manifolds with boundaries.
- Published
- 2024
- Full Text
- View/download PDF
3. Computational study of the post-transition state dynamics for the OH + CH 3 OH reaction probed by photodetachment of the CH 3 O - (H 2 O) anion.
- Author
-
Murakami T and Takayanagi T
- Abstract
Dissociative photodetachment dynamics simulations were conducted to study the CH
3 O- (H2 O) → CH3 O + H2 O + e- reaction using classical molecular dynamics (MD) and ring-polymer molecular dynamics (RPMD) techniques on two newly formulated neutral potential energy surfaces (PES1 and PES2) by different research groups. While the dissociation dynamics exhibited similarities between classical MD and RPMD, there were noticeable differences in the fluctuation of probability densities for the internal modes due to nuclear quantum effects. Upon comparison of our findings with experimental data concerning the electron binding energy distribution and photofragment relative energy, it suggests that the potential energy landscapes of PES2 are reasonably precise. The time evolution of occupied vibrational states of the H2 O photofragment is presented in this study.- Published
- 2024
- Full Text
- View/download PDF
4. Impaired Fat Absorption from Intestinal Tract in High-Fat Diet Fed Male Mice Deficient in Proglucagon-Derived Peptides.
- Author
-
Nishida K, Ueno S, Seino Y, Hidaka S, Murao N, Asano Y, Fujisawa H, Shibata M, Takayanagi T, Ohbayashi K, Iwasaki Y, Iizuka K, Okuda S, Tanaka M, Fujii T, Tochio T, Yabe D, Yamada Y, Sugimura Y, Hirooka Y, Hayashi Y, and Suzuki A
- Subjects
- Animals, Male, Mice, Sterol Esterase metabolism, Sterol Esterase genetics, Triglycerides metabolism, Mice, Inbred C57BL, Fatty Acids, Nonesterified metabolism, Glucagon-Like Peptide 1 metabolism, Duodenum metabolism, Carnitine O-Palmitoyltransferase metabolism, Carnitine O-Palmitoyltransferase genetics, Adipose Tissue metabolism, Dietary Fats, Glucagon-Like Peptide 2 metabolism, Acyltransferases, Lipase, Diet, High-Fat adverse effects, PPAR alpha metabolism, PPAR alpha genetics, Mice, Knockout, Lipid Metabolism, Liver metabolism, Proglucagon metabolism, Proglucagon genetics, CD36 Antigens metabolism, CD36 Antigens genetics, Intestinal Absorption
- Abstract
(1) Background: Proglucagon-derived peptides (PDGPs) including glucagon (Gcg), GLP-1, and GLP-2 regulate lipid metabolism in the liver, adipocytes, and intestine. However, the mechanism by which PGDPs participate in alterations in lipid metabolism induced by high-fat diet (HFD) feeding has not been elucidated. (2) Methods: Mice deficient in PGDP (GCGKO) and control mice were fed HFD for 7 days and analyzed, and differences in lipid metabolism in the liver, adipose tissue, and duodenum were investigated. (3) Results: GCGKO mice under HFD showed lower expression levels of the genes involved in free fatty acid (FFA) oxidation such as Hsl , Atgl , Cpt1a , Acox1 ( p < 0.05), and Pparα ( p = 0.05) mRNA in the liver than in control mice, and both FFA and triglycerides content in liver and adipose tissue weight were lower in the GCGKO mice. On the other hand, phosphorylation of hormone-sensitive lipase (HSL) in white adipose tissue did not differ between the two groups. GCGKO mice under HFD exhibited lower expression levels of Pparα and Cd36 mRNA in the duodenum as well as increased fecal cholesterol contents compared to HFD-controls. (4) Conclusions: GCGKO mice fed HFD exhibit a lesser increase in hepatic FFA and triglyceride contents and adipose tissue weight, despite reduced β-oxidation in the liver, than in control mice. Thus, the absence of PGDP prevents dietary-induced fatty liver development due to decreased lipid uptake in the intestinal tract.
- Published
- 2024
- Full Text
- View/download PDF
5. Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study.
- Author
-
Harada T, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Mochiyama T, Hirayama M, Foidart JM, and Osuga Y
- Abstract
Objective: To evaluate the efficacy and safety of 24-week cyclic administration of estetrol (E4) (15 mg)/drospirenone (DRSP) (3 mg) in Japanese patients with endometriosis., Design: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study., Setting: Twenty-five study centers in Japan., Patient(s): A total of 162 Japanese women diagnosed with endometriosis., Intervention(s): Participants were randomly allocated to the E4/DRSP group or the placebo group. In the E4/DRSP group, participants were orally administered one tablet containing E4 (15 mg) and DRSP (3 mg) daily for 24 days, followed by one placebo tablet for 4 days for a hormone-free interval, constituting a 1-cycle regimen. One placebo tablet was administered once daily for 28 days to participants in the placebo group. The treatments were continued for six cycles (24 weeks) throughout the confirmatory period., Main Outcome Measure(s): Changes in visual analogue scale (VAS) scores for the most severe pelvic pain (lower abdominal and back pain) from baseline to six treatment cycles at the end of the confirmatory study period., Result(s): Estetrol/drospirenone showed changes in the mean VAS scores for the most severe pelvic pain (-33.2 mm) from baseline to the end of the 6-cycle treatment. The between-group difference was significant (-8.5 mm; 2-sided 95% confidence interval, -16.1 to -0.9 mm), showing superiority to placebo. The responder rates, ≥30% and ≥50% reductions in the VAS scores from baseline, were higher in the E4/DRSP group than in the placebo group: 53.2% vs. 29.6% and 36.4% vs. 12.3%. Objective gynecological findings (induration of the cul-de-sac, pelvic tenderness, and limited uterine mobility) were significantly improved by E4/DRSP treatment, and the proportions of stable and worsened participants were significantly lower than in the placebo group. Estetrol/drospirenone decreased the size of endometriomas and improved quality of life, on the basis of quality of life-related questionnaires and global impression scores. No safety concerns were observed with E4/DRSP treatment. Few differences were observed in the proportion of participants with hemostasis parameters outside the reference range between the E4/DRSP and placebo groups., Conclusion(s): Estetrol/drospirenone effectively treats endometriosis-associated pain and improves gynecological findings. Estetrol/drospirenone may be a safe, new option for endometriosis treatment with a potentially decreased risk of thromboembolic events., Clinical Trial Registration Number: jRCT2011210027., Competing Interests: Declaration of Interests T.H. reports a medical writing and clinical trial advisory fee payment on the basis of the medical expert contract from Fuji Pharma Co., Ltd., and case study meeting fee payment on the basis of the medical expert contracts and medical writing fees for other clinical trials other than this manuscript in accordance with the medical expert contract from Fuji Pharma Co., Ltd. T.K. reports a medical writing and clinical trial advisory fee payment on the basis of the medical expert contract from Fuji Pharma Co., Ltd. A.H. reports a medical writing and clinical trial advisory fee payment on the basis of clinical biostatistics expert contract from Fuji Pharma Co., Ltd., and clinical biostatistics educational seminar fee payment on the basis of clinical biostatistics expert contract from Fuji Pharma Co., Ltd. T.T. reports salary and article processing charges from Fuji Pharma Co., Ltd. M.N. reports salary and article processing charges from Fuji Pharma Co., Ltd.; and patent filed with regard to the improvement of cul-de-sac induration, pelvic tenderness, and uterine mobility in subjects with endometriosis complicated by adenomyosis (Fuji Pharma Co., Ltd., and Mithra Pharmaceuticals). T.M. reports salary and article processing charges from Fuji Pharma Co., Ltd. M.H. reports salary and article processing charges from Fuji Pharma Co., Ltd.; and patent filed with regard to the improvement of cul-de-sac induration, pelvic tenderness, and uterine mobility in subjects with endometriosis complicated by adenomyosis (Fuji Pharma Co., Ltd., and Mithra Pharmaceuticals). J.-M.F. is a member of the Board at Mithra Pharmaceuticals and received financial support for the supervision of this study and consulting fees. Y.O. reports a medical writing and clinical trial advisory fee payment on the basis of the medical expert contract from Fuji Pharma Co., Ltd., and case study meeting fee payment on the basis of the medical expert contracts from Fuji Pharma Co., Ltd., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Technical note: Application of an optical hydrophone to ionoacoustic range detection in a tissue-mimicking agar phantom.
- Author
-
Sueyasu S, Kasamatsu K, Takayanagi T, Chen Y, Kuriyama Y, Ishi Y, Uesugi T, Rohringer W, Unlu MB, Kudo N, Yokokawa K, Takao S, Miyamoto N, and Matsuura T
- Subjects
- Acoustics instrumentation, Proton Therapy instrumentation, Phantoms, Imaging, Agar chemistry
- Abstract
Background: Ionoacoustics is a promising approach to reduce the range uncertainty in proton therapy. A miniature-sized optical hydrophone (OH) was used as a measuring device to detect weak ionoacoustic signals with a high signal-to-noise ratio in water. However, further development is necessary to prevent wave distortion because of nearby acoustic impedance discontinuities while detection is conducted on the patient's skin., Purpose: A prototype of the probe head attached to an OH was fabricated and the required dimensions were experimentally investigated using a 100-MeV proton beam from a fixed-field alternating gradient accelerator and k-Wave simulations. The beam range of the proton in a tissue-mimicking phantom was estimated by measuring γ-waves and spherical ionoacoustic waves with resonant frequency (SPIRE)., Methods: Four sizes of probe heads were fabricated from agar blocks for the OH. Using the prototype, the γ-wave was detected at distal and lateral positions to the Bragg peak on the phantom surface for proton beams delivered at seven positions. For SPIRE, independent measurements were performed at distal on- and off-axis positions. The range positions were estimated by solving the linear equation using the sensitive matrix for the γ-wave and linear fitting of the correlation curve for SPIRE; they were compared with those measured using a film., Results: The first peak of the γ-wave was undistorted with the 3 × 3 × 3-cm
3 probe head used at the on-axis and 3-cm off-axis positions. The range positions estimated by the γ-wave agreed with the film-based range in the depth direction (the maximum deviation was 0.7 mm), although a 0.6-2.1 mm deviation was observed in the lateral direction. For SPIRE, the deviation was <1 mm for the two measurement positions., Conclusions: The attachment of a relatively small-sized probe head allowed the OH to measure the beam range on the phantom surface., (© 2023 American Association of Physicists in Medicine.)- Published
- 2024
- Full Text
- View/download PDF
7. Theoretical Study of the Thermal Rate Coefficients of the H 3 + + C 2 H 4 Reaction: Dynamics Study on a Full-Dimensional Potential Energy Surface.
- Author
-
Murakami T, Takahashi S, Kikuma Y, and Takayanagi T
- Abstract
Ion-molecular reactions play a significant role in molecular evolution within the interstellar medium. In this study, the entrance channel reaction, H
3 + + C2 H4 → H2 + C2 H5 + , was investigated using classical molecular dynamic (classical MD) and ring polymer molecular dynamic (RPMD) simulation techniques. We developed an analytical potential energy surface function with a permutationally invariant polynomial basis, specifically employing the monomial symmetrized approach. Our dynamic simulations reproduced the rate coefficient of 300 K for H3 + + C2 H4 → H2 + C2 H5 + , aligning reasonably well with the values in the kinetic database commonly utilized in astrochemistry. The thermal rate coefficients obtained using both the classical MD and RPMD techniques exhibited an increase from 100 K to 300 K as the temperature rose. Additionally, we analyzed the excess energy distribution of the C2 H5 + fragment with respect to temperature to investigate the indirect reaction pathway of C2 H5 + → H2 + C2 H3 + . This result suggests that the indirect reaction pathway of C2 H5 + → H2 + C2 H3 + holds minor significance, although the distribution highly depends on the collisional temperature.- Published
- 2024
- Full Text
- View/download PDF
8. Guest Editorial: Frontiers of Separation Analysis.
- Author
-
Takayanagi T, Todoroki K, Kubo T, and Ueta I
- Published
- 2024
- Full Text
- View/download PDF
9. Evaluating convolutional neural network-enhanced electrocardiography for hypertrophic cardiomyopathy detection in a specialized cardiovascular setting.
- Author
-
Hirota N, Suzuki S, Motogi J, Umemoto T, Nakai H, Matsuzawa W, Takayanagi T, Hyodo A, Satoh K, Arita T, Yagi N, Kishi M, Semba H, Kano H, Matsuno S, Kato Y, Otsuka T, Uejima T, Oikawa Y, Hori T, Matsuhama M, Iida M, Yajima J, and Yamashita T
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Predictive Value of Tests, Adult, Aged, Cardiomyopathy, Hypertrophic diagnosis, Cardiomyopathy, Hypertrophic physiopathology, Cardiomyopathy, Hypertrophic complications, Electrocardiography methods, Neural Networks, Computer
- Abstract
The efficacy of convolutional neural network (CNN)-enhanced electrocardiography (ECG) in detecting hypertrophic cardiomyopathy (HCM) and dilated HCM (dHCM) remains uncertain in real-world applications. This retrospective study analyzed data from 19,170 patients (including 140 HCM or dHCM) in the Shinken Database (2010-2017). We evaluated the sensitivity, positive predictive rate (PPR), and F1 score of CNN-enhanced ECG in a ''basic diagnosis'' model (total disease label) and a ''comprehensive diagnosis'' model (including disease subtypes). Using all-lead ECG in the "basic diagnosis" model, we observed a sensitivity of 76%, PPR of 2.9%, and F1 score of 0.056. These metrics improved in cases with a diagnostic probability of ≥ 0.9 and left ventricular hypertrophy (LVH) on ECG: 100% sensitivity, 8.6% PPR, and 0.158 F1 score. The ''comprehensive diagnosis'' model further enhanced these figures to 100%, 13.0%, and 0.230, respectively. Performance was broadly consistent across CNN models using different lead configurations, particularly when including leads viewing the lateral walls. While the precision of CNN models in detecting HCM or dHCM in real-world settings is initially low, it improves by targeting specific patient groups and integrating disease subtype models. The use of ECGs with fewer leads, especially those involving the lateral walls, appears comparably effective., (© 2024. Springer Nature Japan KK, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
10. Identifying patients with acute aortic dissection using an electrocardiogram with convolutional neural network.
- Author
-
Arita T, Suzuki S, Motogi J, Umemoto T, Hirota N, Nakai H, Matsuzawa W, Takayanagi T, Hyodo A, Satoh K, Yagi N, Otsuka T, Kishi M, Kano H, Matsuno S, Kato Y, Uejima T, Oikawa Y, Hori T, Matsuhama M, Iida M, Yajima J, and Yamashita T
- Abstract
Background: The potential of utilizing artificial intelligence with electrocardiography (ECG) for initial screening of aortic dissection (AD) is promising. However, achieving a high positive predictive rate (PPR) remains challenging., Methods and Results: This retrospective analysis of a single-center, prospective cohort study (Shinken Database 2010-2017, N = 19,170) used digital 12-lead ECGs from initial patient visits. We assessed a convolutional neural network (CNN) model's performance for AD detection with eight-lead (I, II, and V1-6), single-lead, and double-lead (I, II) ECGs via five-fold cross-validation. The mean age was 63.5 ± 12.5 years for the AD group (n = 147) and 58.1 ± 15.7 years for the non-AD group (n = 19,023). The CNN model achieved an area under the curve (AUC) of 0.936 (standard deviation [SD]: 0.023) for AD detection with eight-lead ECGs. In the entire cohort, the PPR was 7 %, with 126 out of 147 AD cases correctly diagnosed (sensitivity 86 %). When applied to patients with D-dimer levels ≥1 μg/dL and a history of hypertension, the PPR increased to 35 %, with 113 AD cases correctly identified (sensitivity 86 %). The single V1 lead displayed the highest diagnostic performance (AUC: 0.933, SD: 0.03), with PPR improvement from 8 % to 38 % within the same population., Conclusions: Our CNN model using ECG data for AD detection achieved an over 30% PPR when applied to patients with elevated D-dimer levels and hypertension history while maintaining sensitivity. A similar level of performance was observed with a single-lead V1 ECG in the CNN model., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Suzuki has received lecture fees from Daiichi Sankyo and Bristol-Myers Squibb. Dr. Yamashita has received research funding and/or lecture fees from Daiichi Sankyo, Bayer Yakuhin, Bristol-Myers Squibb, Pfizer, Nippon Boehringer Ingelheim, Ono Pharmaceutical, and Toa Eiyo. J Motogi, T Umemoto, W Matsuzawa, T Takayanagi, A Hyodo, and K Satoh are employee at Nihon Kohden Corporation., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
11. Lead-Specific Performance for Atrial Fibrillation Detection in Convolutional Neural Network Models Using Sinus Rhythm Electrocardiography.
- Author
-
Suzuki S, Motogi J, Umemoto T, Hirota N, Nakai H, Matsuzawa W, Takayanagi T, Hyodo A, Satoh K, Arita T, Yagi N, Kishi M, Semba H, Kano H, Matsuno S, Kato Y, Otsuka T, Hori T, Matsuhama M, Iida M, Uejima T, Oikawa Y, Yajima J, and Yamashita T
- Abstract
Background: We developed a convolutional neural network (CNN) model to detect atrial fibrillation (AF) using the sinus rhythm ECG (SR-ECG). However, the diagnostic performance of the CNN model based on different ECG leads remains unclear. Methods and Results: In this retrospective analysis of a single-center, prospective cohort study, we identified 616 AF cases and 3,412 SR cases for the modeling dataset among new patients (n=19,170). The modeling dataset included SR-ECGs obtained within 31 days from AF-ECGs in AF cases and SR cases with follow-up ≥1,095 days. We evaluated the CNN model's performance for AF detection using 8-lead (I, II, and V1-6), single-lead, and double-lead ECGs through 5-fold cross-validation. The CNN model achieved an area under the curve (AUC) of 0.872 (95% confidence interval (CI): 0.856-0.888) and an odds ratio of 15.24 (95% CI: 12.42-18.72) for AF detection using the eight-lead ECG. Among the single-lead and double-lead ECGs, the double-lead ECG using leads I and V1 yielded an AUC of 0.871 (95% CI: 0.856-0.886) with an odds ratio of 14.34 (95% CI: 11.64-17.67). Conclusions: We assessed the performance of a CNN model for detecting AF using eight-lead, single-lead, and double-lead SR-ECGs. The model's performance with a double-lead (I, V1) ECG was comparable to that of the 8-lead ECG, suggesting its potential as an alternative for AF screening using SR-ECG., Competing Interests: S.S. received lecture fees from Daiichi Sankyo and Bristol-Myers Squibb. T.Y. received research funds and/or lecture fees from Daiichi Sankyo, Bayer Yakuhin, Bristol-Myers Squibb, Pfizer, Nippon Boehringer Ingelheim, Eisai, Mitsubishi Tanabe Pharm, Ono Pharmaceutical, and Toa Eiyo. The remaining authors have nothing to disclose., (Copyright © 2024, THE JAPANESE CIRCULATION SOCIETY.)
- Published
- 2024
- Full Text
- View/download PDF
12. Potential arrhythmic substrate of atrial fibrillation at the left atrial diverticulum.
- Author
-
Takayanagi T
- Subjects
- Male, Humans, Middle Aged, Heart Atria diagnostic imaging, Heart Atria surgery, Recurrence, Diamond, Treatment Outcome, Atrial Fibrillation surgery, Catheter Ablation methods, Diverticulum complications, Diverticulum diagnostic imaging, Diverticulum surgery
- Abstract
Catheter ablation therapy for persistent atrial fibrillation (PeAF) is both difficult and has limited outcomes. The mechanisms underlying the development and persistence of atrial fibrillation (AF) are not fully understood; therefore, ablation strategies are diverse. A 45-year-old man was referred to our hospital for persistent atrial fibrillation to undergo radiofrequency catheter insertion (RFCA). In the first session we conducted pulmonary vein isolation and additional linear ablation, including that of the roof line and posterior inferior line (posterior box lesion) as the stepwise ablation. However, AF was recurred in six months, therefore he was readmitted for second session ablation preoperative 3D computed tomography (CT) scan for drug-refractory PeAF was performed. The additional isolation of the left superior pulmonary vein and potential drivers of AF by mapping wavefront propagation using multipolar catheters by CARTOFINDER (Biosense Webster, Inc, Diamond Bar, CA, USA) was conducted. However, AF did not terminate. Tomography revealed that the left atrial (LA) diverticulum (LAD) was found uniquely. Electrophysiological findings showed focal firing of the myocardial sleeve and LA diverticulum by an approach for defragmented potentials by re-visiting in interval confidence level (ICL) mode included in the electroanatomical mapping system (CARTO 3, Biosense Webster, Inc, Diamond Bar, CA, USA) and the ablation by encircling this site finally made AF terminate. The AF has not recurred for more than 12 months without the use of antiarrhythmic drugs. This case report suggests that additional ablation around substrates in LAD may be effective for treating refractory AF., Competing Interests: The author declares no conflict of interest for this article.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.